AngioDynamics, Inc. (NASDAQ:ANGO) Stock Has Average Target Price of $19.00

Posted by Stanley Muller on Nov 9th, 2026

Shares of AngioDynamics, Inc. (NASDAQ:ANGO – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the five brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $19.00.

Several research firms have commented on ANGO. Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 target price on shares of AngioDynamics in a research report on Friday, October 9th. Wall Street Zen downgraded AngioDynamics from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. HC Wainwright reduced their target price on AngioDynamics from $19.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, October 13th. Zacks Research upgraded AngioDynamics from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Thursday, October 15th.

Check Out Our Latest Analysis on ANGO

AngioDynamics Price Performance

AngioDynamics stock opened at $11.73 on Monday. The company has a market cap of $493.25 million, a PE ratio of -15.04 and a beta of 0.30. The company has a fifty day moving average price of $13.79 and a two-hundred day moving average price of $12.50. AngioDynamics has a 12 month low of $9.39 and a 12 month high of $16.29.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last issued its earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 4.49% and a negative net margin of 10.12%. The business had revenue of $80.92 million for the quarter, compared to analysts’ expectations of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Equities research analysts anticipate that AngioDynamics will post -0.27 earnings per share for the current year.

Insiders Place Their Bets

In other AngioDynamics news, CFO Stephen Trowbridge sold 23,615 shares of the company’s stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of $12.27, for a total value of $289,756.05. Following the completion of the transaction, the chief financial officer owned 280,461 shares of the company’s stock, valued at $3,441,256.47. This represents a 7.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 6.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AngioDynamics

Several institutional investors have recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board bought a new stake in AngioDynamics during the 2nd quarter worth approximately $428,000. Bank of America Corp DE acquired a new stake in AngioDynamics during the 2nd quarter valued at $4,490,000. Western Standard LLC bought a new position in AngioDynamics in the 2nd quarter valued at $5,037,000. Paradigm Capital Management Inc. NY bought a new position in AngioDynamics in the 2nd quarter valued at $8,732,000. Finally, Bank of New York Mellon Corp bought a new position in AngioDynamics in the 2nd quarter valued at $1,619,000. 89.43% of the stock is owned by institutional investors.

AngioDynamics Company Profile

(Get Free Report)

AngioDynamics, Inc is a medical technology company that develops and manufactures minimally invasive devices used in vascular access, peripheral vascular disease treatment, oncology and surgical procedures. Its products are designed to support physicians in diagnosing and treating patients while reducing the need for more invasive interventions.

The company’s portfolio includes the Auryon system for atherectomy and thrombectomy procedures, the NanoKnife system, which uses irreversible electroporation technology for the ablation of certain soft-tissue tumors, and devices for vascular access and the management of procedure-related complications.